Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction aparlimab + tuvonralimab with chemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2600133275Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Clinical complete remission rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600133275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133275.